CD74 is expressed by multiple myeloma and is a promising target for therapy

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6606-6611

  Burton, Jack D ^a   Ely, Scott ^b   Reddy, Praveeu K ^a   Stein, Rhona ^a   Gold, David V ^a   Cardillo, Thomas M ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; IMMUNOGLOBULIN G1; LYMPHOCYTE ANTIGEN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MICE; MULTIPLE MYELOMA; PLASMA CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE; TRITIUM;

EID: 5144228271     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0182     Document Type: Article

References (31)

1. Claesson L, Larhammer D, Rask L, Peterson PA. cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proc Natl Acad Sci USA 1983;80:7395-9.
2. Strubin M, Mach B, Long EO. The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity. EMBO J 1984;3:869-72.
3. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991;354:392-4.
4. Lamb CA, Cresswell P. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J Immunol 1992;148:3478-82.
5. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabeled antibodies to the MHC class II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300.
6. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ, Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999;98:296-302.
7. Henne C, Schwenk F, Koch N, Moller P. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology 1995;84:177-82.
8. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 1989;49:4568-77.
9. Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999;81:985-92.
10. Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 2001;7:192-201.
11. 90Y. Clin Cancer Res 2001;7:1505-10.
12. Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71.
13. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Molecular Immunol 1995;32:1416-27.
14. Govindan SV, Stein R, Qu Z, et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat 2004;84;173-82.
15. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78.
16. Stein R, Qu Z, Cardillo TM, et al. Anti-proliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood in press 2004.
17. Ely SA, Knowles DM, Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-99.
18. Chomczynski P, Mackey K. Substitution of chloroform by bromochloropropane in the single-step method of RNA isolation. Anal Biochem 1995;225:163-4.
19. Gondo H, Narni F, Lee MS, Blick MB, Cabanillas F, Saunders GF. HLA class II antigen associated invariant chain gene expression in malignant lymphoma. Br J Hematol 1987;67:413-7.
20. Carbone A, Pinto A, Gloghini A, Volpe R, Zagonel V. B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders. Hum Pathol 1992;23:438-48.
21. Stroup R, Sheibani K, Antigenic phenotypes of hairy cell leukemia and monocytoid B-cell lymphoma: an immunohistochemical evaluation of 66 cases. Hum Pathol 1992;23:172-7.
22. Bertero M, Novelli M, Fierro MT, Bernengo MG. Mantle zone lymphoma: an immunohistologic study of skin lesions. J Am Acad Dermatol 1994;30:23-30.
23. Sarker AB, Akagi T, Jeon HJ, et al. Bauhinia purpurea-a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30). Am J Pathol 1992;141:19-23.
24. Venkitaraman AR, Culbert EJ, Feldmann M. A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma. Eur J Immunol 1987;17:1441-6.
25. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76:738-48.
26. Anthony LB, Weltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-32.
27. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-40.
28. 99mTc-LL1. A potential new bone marrow imaging agent. Nucl Med Commun 1997;18:142-8.
29. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
30. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol 1992;149:2391-96.
31. Jiang Z, Xu M, Savas L, LeClair P, Banner BF. Invariant chain expression in colon neoplasms. Virchows Arch 1999;435:32-6.